Tuesday, July 1, 2025 7/1/2025

Anti-Aging Molecule Sirt6 in Neuroprotection in Diabetic Retina

Award Number: R01EY034616
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2023
PERIOD OF PERFORMANCE END DATE: 04/30/2028

Group Awards By:

View Award Description

Anti-Aging Molecule Sirt6 in Neuroprotection in Diabetic Retina - Anti-Aging Molecule Sirt6 in Neuroprotection in Diabetic Retina SUMMARY Diabetic retinopathy (DR) is the most frequent cause of blindness in working age adults in the US today. It was traditionally characterized as microvascular complications due to its clinical manifestation of a period of vascular leakage and degeneration followed by neovascularization. However, recent studies in animal models and patients have shown that retinal neuron injury, in particular retinal ganglion cell (RGC) dysfunction and loss, occurs at early stage of DR and contributes to vision loss. Moreover, though less studies, dysfunction and degeneration of axons of RGC is also evident in diabetes. Current therapies for DR targets clinically significant vascular leakage or neovascularization, which happens much later, and do not protect retinal neurons. This project is to delineate the mechanisms of RGC injury and axonal degeneration during DR in order to identify novel strategies to limit injury and preserve vision. Increasing evidence indicates that stress-induced premature senescence (SIPS) plays a key role in many diseases. There are a few studies reporting SIPS in DR but they are exclusively focused on endothelial cells and have not linked SIPS to DR pathology. There is a significant knowledge gap on how Db induce SIPS in the retina and how to regulate such mechanisms for DR treatment. Sirt6 is a key anti-aging molecule belonging to the sirtuin family that is evolutionarily conserved nicotinamide adenine dinucleotide (NAD)-dependent histone deacetylases and shares homolog with yeast Sir2 protein, a critical regulator of the lifespan of yeast. We now propose to test a hypothesis that Sirt6 suppresses chronic activation of the DNA damage response (DDR)-ATM (ataxia-telangiectasia mutated) pathway to prevent dysfunction/degeneration of RGCs and their axons in DR, partly by inhibiting RGC senescence and mitochondrial dysfunction. We will use our newly developed Sirt6 global and conditional knockout (KO)/overexpression mice, AAV2-mediated gene knockdown, clinic-relevant non-invasive imaging and functional tests, immunohistochemistry, biochemistry and morphometric analyses to test this hypothesis. This study will identify novel roles of Sirt6 and DDR-ATM pathway in RGC and axonal degeneration in DR and establish a link between these them. It will also provide proof-of-concept that boosting anti-aging mechanisms may be utilized to treat DR.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $541,883 )
2025	2025	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Vision Research	000	3	4/11/2025	NON-COMPETING CONTINUATION	$541,883
														Subtotal = $541,883

Issue Date FY: 2024 ( Subtotal = $616,003 )
2024	2024	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Vision Research	000	2	5/21/2024	NON-COMPETING CONTINUATION	$541,883
2024	2024	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Vision Research	001	2	7/24/2024	SUPPLEMENT FOR EXPANSION	$74,120
														Subtotal = $616,003

Issue Date FY: 2023 ( Subtotal = $541,883 )
2023	2023	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Vision Research	000	1	4/5/2023	NEW	$541,883
														Subtotal = $541,883

Grand Total All Awards = $1,699,769

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Anti-Aging Molecule Sirt6 in Neuroprotection in Diabetic Retina

Award Number: R01EY034616

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2023

PERIOD OF PERFORMANCE END DATE: 04/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer